This interview covers healthcare investing shifting from treating symptoms to curing and preventing disease, driven by gene editing and wearables. D.A. Wallach says big pharma has moved from internal R&D to buying startups, creating a $20-30 billion annual buyer market—a huge structural opportunity for VCs. Key holdings: Beam Therapeutics (base editing, just IPO'd), Oura Ring (sleep tracker, invested), and Doctor On Demand (telemedicine, his first healthcare investment).
This report explores the core views of D.A. Wallach on early-stage healthcare investment. He argues that medicine is shifting from "treating disease" to "managing health," with gene therapies (such as CRISPR) and personalized medicine representing key future breakthroughs. Important conclusions incl
D.A. Wallach, former lead singer of Chester French, early Spotify investor and artist-in-residence, has focused on early-stage healthcare investing over the past five years. The core theme of this episode: healthcare is transitioning from a "symptom management" 1.0 era to a "cure and prevention" 2.0 era, driven by gene editing, personalized medicine, and wearable devices. Wallach argues that the fundamental structural opportunity in healthcare investing lies in the fact that large pharmaceutical companies have fully shifted from internal R&D to acquiring startups, creating a $20-30 billion annual forced buyer market — this shift is the most significant change in the industry over the past 20 years, creating an unprecedented structural opportunity for venture capital.
Wallach believes healthcare is undergoing its second major transformation in 200 years — moving from "symptom management" to "cure and prevention."
He notes that medicine and biology are only 200 years old (from cell discovery to DNA identification), while humans have existed for roughly 300,000 years. Major breakthroughs in biological research tools over the past few decades are driving learning at an unprecedented pace, in turn spawning commercially viable breakthrough products.
Core shifts include:
Wallach illustrates this evolution vividly with the case of his wife's family across three generations: the mother's generation benefited from breakthrough drugs (cancer treatment), the wife's generation achieved early screening through genetic testing, and the soon-to-be-born daughter achieved true preventive medicine through IVF embryo selection — "This is the most elegant form of intervention, preventing disease from occurring in the first place."
Wallach argues that gene editing technology is evolving from "cutting DNA" to "rewriting single letters," with the latter offering advantages in treating single-point mutation diseases.
Beam Therapeutics (which went public about two weeks ago), a company he invested in, developed the next generation of CRISPR — base editing. Unlike traditional CRISPR, which cuts double-stranded DNA, base editing "sends a machine into the genome, attaches at a specified location, and then uses an enzymatic reaction to convert a single DNA letter into another," representing a lighter-weight intervention.
Wallach emphasizes that the ethical application of gene editing should proceed in layers:
1. Uncontroversial area: Treating genetic diseases that clearly cause suffering (e.g., his wife's MLH1 mutation, which carries over an 80% cancer risk)
2. More complex area: Embryo selection and editing — he personally used IVF to select embryos without the mutated gene, achieving "true preventive medicine"
He predicts that over the next 100 years, we will pursue editing more complex polygenic diseases, but current technology remains in its early stages.
Wallach points out that public anger over drug price increases stems partly from a fundamental misunderstanding of the pricing mechanism — there is a huge gap between "list price" and "net price."
In his article "The Pricing Paradox," he reveals: a drug's list price at the pharmacy might be $100, the insurer pays $100 to CVS, but the drug company gives the insurer an $80 rebate. Therefore, the insurer's actual net cost is only $20. While list prices keep rising, rebates increase in tandem, so net prices have not risen dramatically — yet the public sees only the soaring list price.
Two different types of drug pricing issues:
| Type | Characteristics | Example |
|---|---|---|
| Breakthrough new drugs | Extremely high production costs (e.g., cell therapy costs $200,000-300,000 per dose), but become cheaper after patent expiry | Cancer cell therapy, list price can reach $1 million per patient |
| Non-innovative drugs | Lack true innovation but prices are artificially inflated | Insulin |
Wallach believes the core problem with the current pricing system is the lack of a price discovery mechanism and multiple monopolies — the legal monopoly from patents, the market exclusivity from FDA approval, and the de facto geographic monopoly of hospitals.
Wallach emphasizes that venture capital returns depend on exits, and exits in healthcare are almost entirely driven by the procurement needs of large pharmaceutical companies.
Over the past 20 years, virtually all large pharma companies have shifted from internal R&D to an acquisition model — buying $20-30 billion worth of startups annually. This creates a "structural opportunity" for venture capital: there is a forced buyer purchasing every year.
In founder selection, Wallach adopts a different model from traditional healthcare venture capital:
He notes that founders in healthcare are often doctors or academic scientists who already have stable jobs and typically do not start companies full-time. Therefore, true entrepreneurs are often "those who take the technology and commercialize it."
Wallach believes the ultimate value of wearable devices lies in enabling very early detection of disease, not just health tracking.
He cites Eric Topol's "car model": modern cars have various sensors that trigger warning lights when something goes wrong. Current healthcare is reactive — doctors only intervene when you are clearly sick. By the time a disease reaches an obvious stage, it is often already difficult to control.
New dimensions being measured:
Wallach himself wears a continuous glucose monitor (non-diabetic use) and has invested in Oura Ring (a sleep tracking ring). He specifically notes that large tech companies are collectively betting on healthcare: 60% of Google Ventures' investments last year were in healthcare, the Apple Watch has an FDA-approved heart application, and Google acquired Fitbit — "Healthcare is the next biggest market for all these companies."
Wallach is cautious about innovation on the healthcare delivery side, believing it is more suited to private equity than venture capital.
Reasons include:
He acknowledges that innovative models like transparent surgery centers are appealing but have not been replicated at scale. He believes product-side innovation (drugs, diagnostics, devices) is where venture capital is truly exciting.
Wallach believes "medical nihilism" is largely untenable — his mother-in-law is living proof saved by breakthrough drugs — but overtreatment is a real problem.
Examples of overtreatment:
He specifically warns about the false positive risk of liquid biopsy: even with 99% specificity, if 300 million Americans are tested, 1% (3 million people) will receive false positives, leading to unnecessary biopsies, CT scans, or even surgeries.
| Position | Guest Stance | Key Data |
|---|---|---|
| Beam Therapeutics | Bullish (invested, participated in IPO) | Develops base editing technology, next-gen CRISPR; IPO'd about two weeks ago |
| Doctor On Demand | Bullish (invested) | Telemedicine service, first healthcare investment |
| Oura | Bullish (invested via Will Smith's Dreamers Fund) | Sleep tracking ring |
| Spotify | Bullish (early investor) | Converted free music listeners into paying subscribers |
| SpaceX | Bullish (early investor) | Satellite internet; Iridium failed 30 years ago but technology is now mature |
| Google/Apple/Microsoft | Neutral observer | All making large-scale moves in healthcare |
1. "Over the past 20 years, all large pharma companies have shifted from internal R&D to an acquisition model, creating a $20-30 billion annual forced buyer market" — This is the most fundamental structural opportunity in healthcare venture capital, with no reason to believe it will stop.
2. "There is a huge gap between list price and net price — list prices keep rising but rebates increase in tandem, so net prices have not risen dramatically" — Public anger over drug prices stems partly from a misunderstanding of the pricing mechanism; the real core issue is the lack of a price discovery mechanism.
3. "In healthcare investing, exits are harder than entries — your returns depend on how you exit" — The core of Wallach's investment methodology: first figure out what large pharma will need to buy in the next 5-10 years, then decide what to invest in.
4. "100 years from now, most babies may be born through reproductive technology" — Wallach's aggressive prediction on the adoption rate of assisted reproductive technology, based on continued progress in IVF and genetic screening.
5. "The healthcare delivery side is a good place for private equity, not venture capital — because almost everyone has an incentive to raise prices" — A pessimistic view on delivery-side innovation: stable and profitable but lacking structural change momentum.
6. "Even with 99% specificity, testing 300 million people still yields 3 million false positives — the false positive risk of liquid biopsy is a real threat" — A quantitative warning about the overtreatment risk of early cancer detection technology.
7. "Large tech companies (Apple, Google, Microsoft) are collectively betting on healthcare — it's the next biggest market in their eyes" — Wallach sees this as an important signal that healthcare investment prospects are strong.
8. "The media industry has a pendulum effect between content and distribution — the pendulum has now swung back to the content side" — An investment lesson from the music industry: after distribution platforms saturate, content creators regain pricing power.